2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
EQS-Ad-hoc: Merck KGaA / Key word(s): Half Year Results Darmstadt, July 26, 2024: Based on a very strong second quarter of 2024 with net sales of EUR 5.352 bn resulting in an EBITDA pre1 of EUR 1.509 bn and an EPS pre1 of EUR 2.20, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2024. The main driver is a very strong operating performance of Healthcare and Electronics compared to consensus. The performance of Life Science is within expectations. The strong operating performance of Healthcare more than offset the provision equal to a mid-double-digit million euro amount associated with xevinapant. The Company now projects net sales of approx. EUR 20.7 - 22.1 bn (previously EUR 20.6 – 22.1 bn). EBITDA pre1 is anticipated to grow to approx. EUR 5.8 – 6.4 bn for the Group (previously "EUR 5.7 – 6.3 bn"). EPS pre1 is projected to amount to approx. EUR 8.20 – 9.30 (previously "EUR 8.05 – 9.10"). The Company will publish Q2 / 2024 figures as scheduled on 1 August 2024.
1 EBITDA pre and EPS pre are alternative performance measures not defined by international accounting standards, used by the Company to improve the comparability of business performance over time and within the industry. EBITDA pre means earnings before interest, income tax, depreciation and amortization as well as adjustments (Ergebnis vor Zinsen, Ertragsteuern, Abschreibungen und Anpassungen). EPS pre means profit after tax including adjustments per theoretical shares outstanding (see Merck Annual Report 2023). Esther Döringer Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany Phone: +49 151 1454 7809 Email: esther.doeringer@merckgroup.com Internet: https://www.merckgroup.com/en ISIN: DE0006599905 WKN: 659990 Indices: DAX Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX End of Inside Information
26-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151 72 - 2702 |
| E-mail: | insiderregister@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 1955415 |
| End of Announcement | EQS News Service |
|
|
1955415 26-Jul-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
